UroGen Pharma (NSDQ:URGN) announced today that it entered into a funding agreement with RTW Investments worth $75 million. Princeton, N.J.-based UroGen’s agreement with RTW will see the biopharmaceutical company receive $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto (mitomycin) for pyelocalyceal […]
Bigfoot Biomedical raises $57M to support its diabetes management tech
Bigfoot Biomedical announced today that it secured $57 million in financing as it works toward commercializing its diabetes management program. Madryn Asset Management provided the financing for Bigfoot, which is developing the Bigfoot Unity diabetes management program designed to simplify and connect aspects of insulin management to enable personalized, proactive and remote patient care, according […]
Eyenovia touts study of pupil dilation treatment
Eyenovia (NSDQ:EYEN) today announced positive results from a study of its microdose array print (MAP) pupil dilation technology. Study data, published in Therapeutic Delivery, revealed pooled results from two prospective, double-masked, controlled, cross-over superiority Phase 3 studies. Those results concluded that a micro-dosed fixed-combination of tropicamide 1% and phenylephrine 2.5% for pupil dilation (mydriasis) is safe and […]
Oramed reaches 25% randomization in oral insulin trial, expects topline results in 2022
Oramed Pharmaceuticals (NSDQ:ORMP) announced that it reached 25% randomization in the enrollment for its oral insulin capsule trial. New York-based Oramed’s Phase 3 ORA-D-013-1 study for the ORMD-0801 oral insulin capsule for the treatment of Type 2 diabetes has planned for 675 patients overall, reaching a quarter of that mark in enrollment so far with […]
Sandoz announces in-licensing of Kindeva respiratory inhalation aerosol
Sandoz announced that it is in-licensing the commercial distribution rights to a respiratory inhalation medicine from Kindeva Drug Delivery. Princeton, N.J.-based Sandoz in-licensed the rights to the brand and authorized generic of Proventil HFDA (albuterol sulfate) inhalation aerosol, which is immediately available to U.S. patients, according to a news release. Albuterol sulfate is used to […]
HTX Urology set to participate in study for Urotronic’s prostate treatment device
Urotronic announced that HTX Urology is participating in an FDA-cleared study for a minimally invasive device for treating enlarged prostates. Plymouth, Minn.-based Urotronic’s Optilume BPH (benign prostatic hyperplasia, otherwise known as enlarged prostate) catheter system is an outpatient procedure designed to combine balloon dilation to open the prostate and local drug delivery to maintain symptom […]
Graphite Bio closes $150M Series B
Graphite Bio announced that it closed an oversubscribed Series B financing round with proceeds totaling $150 million. South San Francisco-based Graphite Bio’s funding is earmarked for the expansion and advancement into the clinic of its pipeline of investigational targeted gene integration therapies with curative potential for serious diseases, according to a news release. The company […]
Italfarmaco, Luye enter commercialization pact for transdermal Alzheimer’s treatment
Italfarmaco Group and Luye Pharma announced today that they entered into a commercialization agreement for Rivastigmine MD. Under the agreement, Milan, Italy-based Italfarmco receives exclusive rights to commercialize the Rivastigmine multi-day transdermal patch in four European companies, according to a news release. Italfarmaco gains the rights to commercialize in Germany, Italy, Portugal and Greece under […]
Glooko raises $30M Series D
Diabetes and obesity management tech developer Glooko announced today that it raised $30 million in a Series D financing round. Palo Alto, Calif.-based Glooko, which develops remote patient monitoring and chronic care management products including data management technologies for insulin delivery devices, said in a news release that proceeds from the financing will be used […]
Intec Pharma, Decoy Biosystems agree to merger
Intec Pharma (NSDQ:NTEC) announced that it entered into a definitive agreement over a merger with Decoy Biosystems. Jerusalem-based Intec Pharma said in a news release that the combined company is slated to grow an immunotherapy platform to battle a variety of tumor types and chronic viral infections with Decoy bringing to the table multi-targeted products […]
